GI CANCERS

A number of studies are challenging the current gastrointestinal cancer treatment landscape.

A phase 1b study will investigate PTM-101, a directed administration of paclitaxel, in patients with nonmetastatic pancreatic cancer.

The blood-based ctDNA test delivered high rates of sensitivity and specificity with long lead times in detecting minimal residual disease in patients with colorectal cancer.

The FDA has set a target action date of April 3, 2025, for the supplemental new drug application of cabozantinib for the treatment of neuroendocrine tumors.

The Precision Promise and LAPIS studies failed to meet their primary end points of overall survival among patients with pancreatic cancer treated with the investigational agent pamrevlumab.

The ASPEN-06 trial found that adding evorpacept to trastuzumab, ramucirumab, and paclitaxel significantly improved overall response rates and duration of response in patients with previously treated HER2-positive advanced gastric or gastroesophageal junction cancer.

Avutometinib plus defactinib shows promising early results in pancreatic cancer, earning an orphan drug designation from the FDA.

The FDA approval of Guardant Shield marks the second blood-based diagnostic test for colorectal cancer in those age 45 and older at average risk of the disease.

A new dendritic cell vaccine has shown promising results in extending survival for pancreatic cancer patients by stimulating the immune system to fight tumor cells.

Patrick Boland, MD, discussed the practice-changing implications of the phase 3 ESOPEC study comparing FLOT vs CROSS regimens for the treatment of esophageal adenocarcinoma.

A dendritic cell vaccine called DOC1021 shows early promise in treating pancreatic cancer and has received a fast track designation from the FDA.

The ESOGUARD BE-1 trial demonstrated that the EsoGuard test, combined with EsoCheck, effectively detects esophageal precancer and supports its use as a screening tool to prevent esophageal cancer.

The FDA has received a 505(b)(2) new drug application seeking approval for a lutetium Lu 177 dotatate injection as a potential treatment for SSTR-positive gastroenteropancreatic neuroendocrine tumors.

MRG004A, a novel antibody-drug conjugate, elicited antitumor activity and had manageable toxicities when used in heavily pretreated patients with multiple tumor types with high tissue factor.

Final analysis from KEYNOTE-585 revealed that event-free survival (EFS) was not significantly improved.

Modified FOLFIRINOX with nivolumab in the neoadjuvant setting was associated with favorable rates of R0 resection in patients with borderline resectable pancreatic cancer.

Mark A. Lewis, MD, discusses the exciting progress of dostarlimab in treating rectal cancer.

mKRAS-specific T-cell responses that were produced by ELI-002 7P correlated with tumor biomarker responses among patients with pancreatic and colorectal cancer.

Zanidatamab therapy led to confirmed responses, disease control, and favorable overall survival in pretreated HER2+ biliary tract cancer in an update of the HERIZON-BTC-01 trial.

Perioperative chemotherapy with improved OS vs neoadjuvant chemoradiation in resectable esophageal cancer.

Shubham Pant, MD, discusses background on zanidatamab and findings from the HERIZON-BTC-01 trial of the agent for HER2-positive biliary tract cancer treatment.

Zolbetuximab could become the first CLDN18.2-targeted therapy approved for this patient population in the US.

VCN-01, an adenovirus therapy, received fast track designation from the FDA for treating metastatic pancreatic cancer in combination with standard chemotherapy.

The FDA has withdrawn the approval for infigratinib to treat patients with cholangiocarcinoma. A phase 3 study comparing it to standard treatment has also been halted.

The combination of pembrolizumab, trastuzumab, and chemotherapy showed significant improvement in overall survival vs placebo in patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma.

Results from a 3-year follow-up of the TOPAZ-1 trial showed that treatment with durvalumab plus chemotherapy in advanced biliary tract cancer continued to improve overall survival vs chemotherapy alone.

During a Case-Based Roundtable® event, David Zhen, MD, discussed how treatment of upper gastrointestinal cancer with pembrolizumab and chemotherapy is impacted by PD-L1 composite positive score, in the second article of a 2-part series.

Preoperative low-dose radiation did not deliver response rates comparable with higher doses of radiation among patients undergoing surgical resection for esophageal cancer.

Rivoceranib did not produce a statistically significant improvement in overall survival vs placebo, according to findings from the phase 3 ANGEL trial in gastric or gastroesophageal junction cancer.